The myeloproliferative neoplasms (MPNs) session this morning will bring together a full spectrum of timely topics, from novel therapies in polycythemia vera (PV) and essential thrombocythemia (ET) to new questions about transplantation, according to Gabriela Hobbs, MD, of Massachusetts General Hospital and the SOHO 2025 MPN session co-chair.
“We’re going to cover a lot of topics that are very relevant right now for the management of patients with MPN,” Dr. Hobbs said. “We’ll start by talking about the novel therapies being developed for PV and ET and then move into the excitement around new therapies to manage anemia in myelofibrosis.”
“With four different JAK inhibitors now available for myelofibrosis, Francesca Palandri, MD, PhD, will talk about how to optimize JAK inhibitor therapy because there are many questions about which should be used in which patients and in what order,” she said. “That will segue into the talk from John O. Mascarenhas, MD, focused on combination therapy, since there’s been a lot of clinical trials combining JAK inhibitors with novel agents. Ffinally, Vikas Gupta, MD, FRCP, FRCPath, will round out the session with a presentation on transplantation—when we should refer patients, when to consider it, and who are the best candidates.”
On abstracts, Dr. Hobbs noted a wide range: updates on pelabresib and BET inhibitors, hepcidin-regulating therapies for myelofibrosis and PV, and ropeginterferon versus anagrelide in ET. They will also see observational and retrospective studies, including disparities in mortality of patients with PV in the United States, community oncology experiences in myelofibrosis, gender-based molecular differences, and access barriers in MPNs.
It promises to be an exciting session, Dr. Hobbs said.
Visit the SOHO 2025 meeting news page for more coverage from the meeting.
